熱門資訊> 正文
BridgeBio肿瘤治疗公司GAAP每股收益为-0.49美元
2026-03-06 06:59
- BridgeBio Oncology Therapeutics, Inc. press release (BBOT): GAAP EPS of -$0.49.
- Cash Position: As of December 31, 2025, BBOT had cash, cash equivalents and marketable securities totaling $425.5 million, which is expected to provide cash runway into 2028.
- Research and development (R&D) expenses: R&D expenses were $38.1 million for the fourth quarter of 2025 compared to $19.5 million for the fourth quarter of 2024. The increase in expenses was primarily due to increases in clinical trial expenses and manufacturing expenses for BBO-8520, BBO-11818, and BBO-10203.
- General and administrative (G&A) expenses: G&A expenses were $5.3 million for the fourth quarter of 2025 compared to $2.3 million for the fourth quarter of 2024. Changes in G&A expenses reflect the initiation of BBOT's standalone operations and de-SPAC transaction.
- Net Loss: Net loss was $38.8 million for the fourth quarter of 2025 compared to $19.7 million for the fourth quarter of 2024.
More on BridgeBio Oncology Therapeutics, Inc.
- BridgeBio Oncology Therapeutics, Inc. (BBOT) Discusses Clinical Data Updates for BBO-8520, BBO-11818, and BBO-10203 Transcript
- BridgeBio Oncology Therapeutics: Promising KRAS Drug Developer - In My View, At Least
- BridgeBio Oncology gains outperform rating from Raymond James
- Seeking Alpha’s Quant Rating on BridgeBio Oncology Therapeutics, Inc.
- Historical earnings data for BridgeBio Oncology Therapeutics, Inc.
推薦文章
美股機會日報 | 特朗普再放豪言！正與伊朗談判，並收到伊方「大禮」；特斯拉機器人再迎新進展！馬斯克稱有望明年實現量產
一圖看懂 | 單季盈利承壓！拼多多Q4營收1239億元同比增12%，調后淨利卻下跌12%；高管稱「力爭三年再造一個拼多多」
財報前瞻 | 美團Q4財報將放榜！大摩、高盛逆勢力挺股價，當前美團已嚴重超跌？
中東戰火中金價狂瀉11%！創43年最慘周跌，避險邏輯崩塌還是黃金坑？
美股機會日報 | 中東硝煙將散？以官員稱美方4月9日結束對伊戰爭！海力士擬籌資百億赴美上市，豪擲80億美元鎖定阿斯麥光刻機！
一圖看懂 | 連續5個季度破千億！小米Q4營收1169億創歷史新高；淨利大增43.8%至63億元
無論美伊談判真假！華爾街已從特朗普引發的五分鍾狂飆獲得明確信號？
麥格理：緊張局勢緩和后布倫特原油底部在每桶85至90美元
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
